The global Dental Lasers Market size is expected to reach USD 1,530.6 million by 2026, according to a new report by Grand View Research Inc. It is projected to register a CAGR of 6.5% during the forecast period. Rising application of dental lasers for the treatment of dental diseases and procedures, such as cavity preparation, dentinal hypersensitivity, restorative removal, growth modulation, and caries prevention, is contributing to the growth. In addition, increasing adoption in hyperplastic tissue removal, wound healing, photostimulation of herpetic lesions, and photodynamic therapy for malignancies is anticipated to fuel the demand.
Advantages such as high efficiency, less bleeding, better control of soft tissue, and comfortable treatment are anticipated to further fuel the demand for dental lasers. Additionally, many insurance policies cover the usage of dental lasers for conservative soft tissue, therefore fueling market growth. Technological advancements are predicted to offer lucrative opportunities in the forthcoming years. Growing use of lasers in dentistry domain coupled with increasing acceptance of devices with novel technologies by dental surgeons are few emerging trends witnessed in the market. Request a free sample copy or view report summary: Dental Laser Market Report Dental Laser Market Report Highlights
0 Comments
The global Intravascular Catheters Market size is expected to reach USD 8.8 billion by 2025, according to a new report by Grand View Research, Inc., registering an 11.8% CAGR during the forecast period. Increasing number of surgical procedures requiring catheters, growing awareness about hospital-acquired infections, and increasing coverage of healthcare insurance are some of the factors contributing to the demand for intravascular catheters from 2019 to 2025. The market is also expected to be driven by increasing number of patients undergoing cardiovascular as well as urological procedures and rising incidents of trauma injuries.
Short Peripheral Intravascular Catheters (PIVC) dominated the market with a revenue of USD 2.8 billion in 2018, on account of lower infection risk associated with these products. In addition, short PIVCs are preferred over other catheters due to their quick discharge and short dwelling time. This product segment is expected to witness lucrative CAGR between 2018 to 2025 as a consequence of increasing concerns over catheter-associated bloodstream infections leading to catheter colonization. Hospitals dominated the market on the basis of end use in 2018, with a revenue of USD 2.5 billion. The trend is likely to continue over the forecast period owing to increase in number of surgical procedures requiring catheters, growing health insurance coverage, and rising hospital admissions. Ambulatory Surgical Centers (ASC) are anticipated to witness the fastest growth, with a CAGR of 13.5% through 2025. Surgical procedures are cheaper in ASCs as compared to hospitals. As a result, the market is expected to witness a rise in adoption of surgical procedures in ASCs, which in turn is anticipated to drive demand for intravascular catheters over the forecast period. Asia Pacific dominated the intravascular catheters market with a revenue of USD 1.2 billion in 2018, owing to high patient base, increasing investments in healthcare infrastructure, growing insurance coverage, and availability of reimbursements. This region is anticipated to witness lucrative growth due to its high potential in overcoming unmet medical needs among patients suffering from cardiovascular and urological diseases as well as trauma injuries. China dominated the APAC market with a 23.3% revenue share in 2018 owing to high unmet medical needs, growing awareness about hospital-acquired infections, and increase in healthcare accessibility. Thus, a high population base with unmet medical needs is expected to drive demand for intravascular catheters between 2018 to 2025. Request a sample copy or view summary of this report@ https://www.grandviewresearch.com/industry-analysis/intravascular-catheters-market Further key findings from the report suggest:
The global Hunter Syndrome Treatment Market size is expected to reach a value of USD 1.52 billion by 2026, expanding at a CAGR of 7.1%, according to a new report by Grand View Research, Inc. High unmet needs, robust pipeline, increasing awareness about this rare disease and growing R&D activities for the development of novel therapies are expected to drive market growth over the forecast period.
Hunter syndrome, also referred as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by the missing or malfunctioning iduronate-2-sulfatase enzyme. According to the data published by the National Institute of Neurological Disorders and Stroke, MPS II syndrome occurs in around 1 in every 100,000 to 150,000 male births. Presently, there are no approved curative therapies for the treatment of Hunter syndrome. The available treatment options such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT) are focused on providing symptomatic relief and management of complications associated with disease progression. Shire plc’s Elaprase (idursulfase) is the only key drug available for the treatment of Hunter syndrome worldwide, with GC Pharma’s Hunterase (idursulfase beta) being approved only in South Korea. Key players are focused on extensive R&D activities for product development and gaining approval as novel therapies. Launch of such novel therapies in the near future is expected to significantly fuel the Hunter syndrome treatment market growth. For instance, in May 2018, REGENXBIO Inc. received the U.S. FDA’s Fast Track designation for its novel drug candidate RGX-121, indicated for the disease treatment. Request a sample copy or view summary of this report@ https://www.grandviewresearch.com/industry-analysis/hunter-syndrome-treatment-market Further Key Findings from the Study Suggest:
The global Diabetic Foot Ulcer Treatment Market size is expected to reach a value of USD 6.82 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.2% during the forecast period. Rising prevalence of diabetes, increasing healthcare expenses, and rapidly growing geriatric population worldwide are some of the major factors driving the diabetic foot ulcer treatment market.
Diabetic foot ulcers are one of the most common foot injuries that is caused due to diabetes mellitus. Management of diabetic foot ulcers aims at fast healing and wound closure, by adopting a multidisciplinary therapeutic approach so as to avoid amputation. Among different types of treatment options available, biologics held the largest share in the diabetic foot ulcer treatment market in 2017. This can be attributed to strong revenue generated by growth factors that are prescribed worldwide for their ability to promote generation of new cells and achieve wound closure. Therapy devices and wound care dressings also offer significant commercial opportunity due to their cost-effectiveness, ease of availability, and wide use in combination with other treatments at every level of wound care management. Among different ulcer types, neuro-ischemic ulcers led the market in 2017 with more than 50.0% market share due to higher patient population suffering from the ulcer type globally. North America represented the largest share in the global market in 2017 owing to rising prevalence of diabetes, growing geriatric cohort, increased investment in R&D of novel therapies, and developed healthcare facilities. Request a free sample copy or view report summary: Diabetic Foot Ulcer Treatment Market Report Diabetic Foot Ulcer Treatment Market Report Highlights
The global Hereditary Angioedema Therapeutic Market size is expected to reach USD 4.2 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting an 8.1% CAGR during the forecast period. Growing initiatives by international patient organizations to improve awareness about hereditary angioedema (HAE) among patients and healthcare providers is likely to be a high impact rendering driver for the market.
Patient advocacy organizations affiliated to HAE International (HAEi) are focusing on campaigns through both print and social media in order to raise awareness levels for hereditary angioedema. HAEi has also introduced family testing tools for improving patient awareness levels, which is likely to help in providing accurate diagnosis and optimal medical treatment. Pharmaceutical and biotechnology companies such as CSL Limited, Pharming Group N.V., and Shire Plc. engaged in development of therapies for HAE have also lent their support and collaborated with the hereditary angioedema community so as to create effective diagnosis process and treatment for the condition. Universities in different countries across the globe are collaborating with each other in order to develop new therapies for the management of hereditary angioedema attacks. For instance, in 2018, 26 universities from Europe, Australia, and Canada collaborated on an international study to develop a novel oral therapy for prevention of the condition. Measures undertaken by countries for improving patient access to new therapies, along with modification in regulatory guidelines for facilitating faster drug review and approval for HAE, are expected to contribute to market growth. For instance, in July 2018, China’s National Health Commission (NHC) and State Drug Administration (SDA) allowed pharmaceutical drug manufacturers to file for New Drug Application (NDA) for therapies for rare diseases whose treatment is currently not available in the country. The decision has allowed drug manufacturers to use clinical trial data from outside China while filing for NDA. Request a sample copy or view summary of this report@ https://www.grandviewresearch.com/industry-analysis/hereditary-angioedema-hae-therapeutics-market Further key findings from the report suggest:
Heart Failure POC & LOC Devices Market: Industry Size, Share, Demand, Analysis & Forecast, 202511/5/2020 The global Heart Failure POC & LOC Devices Market size is expected to reach USD 129.69 million by 2025 and is projected to grow at a CAGR of 16.2%, according to a new report by Grand View Research, Inc. A paradigm shift in diagnostic sectors from late-stage disease detection to early identification of diseases as a viable strategy to curb rising healthcare costs has driven the market. This shift has led to the development of disposable and low-cost LOC devices that integrate various sensors and associated accessories in a single space for detection of the cardiac biomarkers from a single specimen to evaluate the risk of having a heart attack.
Furthermore, the development of predictive modeling techniques-based decision support software to analyze the data measured by the LOC assays to enable therapy monitoring is one of the key market drivers. Also, ongoing studies on the application of saliva-based nano-biochip tests for measuring myocardial infarction is driving organic revenue growth. POC testing exhibits potential savings across various settings, including hospitals, general practice, and remote areas. In the U.S., the employment of POC devices resulted in a 20% decrease in hospital admissions to the chest pain unit, resulting in substantial savings in time and costs. In the cardiac observation unit (U.S.), the implementation of POC troponin testing helped reduce hospital stays, decrease admission rates, and remove the need for multiple costly procedures, resulting in 25% cost saving per patient. Furthermore, the integration of smartphones and apps in POC diagnostics for managing the cardiac health of an individual is one of the significant innovations in Heart Failure POC & LOC Devices market. Request a sample copy or view summary of this report@ https://www.grandviewresearch.com/industry-analysis/heart-failure-poc-loc-devices-market Further key findings from the report suggest:
The global Subdermal Contraceptive Implants Market size is expected to reach USD 969.2 million by 2026, according to a new report by Grand View Research, Inc., registering a 3.2% CAGR over the forecast period. Introduction of several modern contraceptives in the market, growing awareness about various birth control methods, and high per capita income are some of the key factors driving the market for subdermal implants for birth control.
According to the Guttmacher Institute, in 2014, approximately 20 million women needed publicly funded contraceptive services. According to CDC, in 2017, nearly 46.9 million women in the U.S. were using at least one method of contraception. Subdermal implant is a long-term birth control option for women. Subdermal implants for contraception are in the form of polymer capsules or rods placed under the skin. The progestational hormone is released at a slow and stable rate, providing effective contraception for 1-5 years. Publicly funded family planning services help women avoid or plan pregnancies. In 2012, the South Carolina Department of Health and Human Services (SCDHHS) revised the cost associated with Medicaid payment policy for immediate postpartum insertion of Long-Acting Reversible Contraception (LARC). Under this new reimbursement policy, providers are allowed to bill for the insertion procedure and the cost of an IUD or an implant, in addition to the Diagnosis Related Group (DRG) by using J-codes with a family planning modifier. Implants are the most widely used contraceptive methods by women in sub-Saharan Africa owing to public-private partnerships between manufacturers, donors, governments, and international agencies, which helps lower commodity cost and increase product availability. Contraceptive usage has increased in South Africa, Malawi, and Rwanda. According to PLOS.org, in Malawi, the use of the Long-acting Reversible Contraception (LARC) method reached 10.21% in urban areas in 2016 and 9.66% in rural areas. In 2012, an initiative called Family Planning 2020 (FP2020) was launched to give 120 million women access to modern contraceptive methods by 2020. Request a sample copy or view summary of this report@ https://www.grandviewresearch.com/industry-analysis/subdermal-contraceptive-implants-market Further key findings from the report suggest:
The global Next-Generation Sequencing (NGS) Sample Preparation Market size is expected to reach USD 5.80 billion by 2025, expanding at a CAGR of 11.19% over the forecast period according to a new report by Grand View Research, Inc. Development of companion diagnostics and personalized medicine is expected to enhance the adoption of next-generation sequencing protocols in clinical practice. NGS technology is widely applicable in theranostics domain thus leading to growth in NGS sample preparation market.
In addition, an increase in sequencing capacity and speed has led to a rise in demand for high-throughput NGS sample handling solutions. Therefore, key players are focused on the development of automated platforms for sample preparation for next-generation sequencing. For instance, the Bravo NGS manufactured by Agilent Technologies, Inc. efficiently automates library preparation for NGS implementation and reduces the overall time of the process. A laboratory technician can use Bravo NGS to prepare whole genome libraries for nearly 1,000 samples every week. The system also reduces variability by nearly 39% as compared to other manual methods. Request a sample copy or view summary of this report@ https://www.grandviewresearch.com/industry-analysis/next-generation-sequencing-sample-preparation-market Further Key Findings from the Report Suggest:
The global Cranial Clamps Market is anticipated to reach USD 319.30 million by 2026, registering a CAGR of 4.7% during the forecast period, according to a new report by Grand View Research, Inc. increasing incidence of road accidents along with the prevalence of brain tumors and Traumatic Brain Injuries (TBIs) is anticipated to boost the market growth.
As per the National Health Portal, India, the incidence of central nervous system (CNS) tumors is 5 to 10 per 100,000 population. According to the Centers for Disease Prevention and Control (CDC), in 2014, about 2.87 million TBI related Emergency Department Visits, Hospitalizations and Deaths (EDHD) in U.S. Cranial clamps are used during c; otolaryngology or ear, throat, and nose procedures; and orthopedics or musculoskeletal system related surgeries for providing the rigid fixation to the neck and head. Cranial clamps enables patient immobilization and reduces the risk of soft tissue injuries during the micro procedures. Increasing prevalence of brain and CNS tumors and TBIs is expected to drive the growth of the cranial clamps market over the forecast period. Increasing initiatives by the government and non-profitable organizations for spreading awareness and the treatment of neurological diseases are also projected to fuel the market growth. For instance, new model of care for neurological services was launched in Ireland by the director-general of Health Service Executive (HSE). Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/cranial-clamps-market Further key findings from the study suggest:
|
Archives
October 2023
|